Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Obstetrics and Gynecology
Volume 2018, Article ID 2385048, 5 pages
https://doi.org/10.1155/2018/2385048
Case Report

Elevated CA 125 in a CASE of Leaking Endometrioma

1Liverpool Hospital, Australia
2Westmead Hospital, Australia

Correspondence should be addressed to Svetha Rao; moc.liamg@1oarahtevs

Received 12 June 2018; Accepted 15 August 2018; Published 12 September 2018

Academic Editor: Maria Grazia Porpora

Copyright © 2018 Svetha Rao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Nisenblat, P. M. Bossuyt, R. Shaikh, C. Farquhar, V. Jordan, C. S. Scheffers et al., “Blood biomarkers for the non-invasive diagnosis of endometriosis,” Cochrane Database of Systematic Reviews, no. 5, 2016. View at Google Scholar
  2. R. C. Bast Jr., D. Badgwell, Z. Lu et al., “New tumor markers: CA125 and beyond,” International Journal of Gynecological Cancer, vol. 15, Suppl 3, no. 6, pp. 274–281, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. R. L. Barbieri, J. M. Niloff, R. C. Bast Jr., E. Scaetzl, R. W. Kistner, and R. C. Knapp, “Elevated serum concentrations of CA-125 in patients with advanced endometriosis,” Fertility and Sterility, vol. 45, pp. 630–634, 1986. View at Google Scholar
  4. C. M. Boyer, R. C. Knapp, and R. C. Bast Jr., “Biology and immunology,” in Practical Gynecologic Oncology, J. S. Berek and N. F. Hacker, Eds., pp. 89-90, Williams & Wilkins, Baltimore, MD, USA, 2nd edition, 1994. View at Google Scholar
  5. J. Johansson, M. Santala, and A. Kauppila, “Explosive rise of serum CA 125 following the rupture of ovarian endometrioma,” Human Reproduction, vol. 13, pp. 3503-3504, 1998. View at Google Scholar
  6. R. J. Kashyap, “Extremely elevated serum CA125 due to endometriosis,” The Australian & New Zealand Journal of Obstetrics & Gynaecology, vol. 139, pp. 269-270, 1999. View at Google Scholar
  7. H. Kurata, M. Sasaki, H. Kase, Y. Yamamoto, Y. Aoki, and K. Tanaka, “Elevated serum CA125 and CA19-9 due to the spontaneous rupture of ovarian endometrioma,” European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 105, no. 1, pp. 75-76, 2002. View at Google Scholar
  8. H. Cengiz, Ş. Yıldız, L. Yaşar, M. Ekin, and C. Kaya, “Extremely elevated serum CA125 and CA19-9 levels following the rupture of ovarian endometrioma: a case report,” Gaziantep Medical Journal, vol. 18, no. 3, pp. 189-190, 2012. View at Google Scholar
  9. A. K. Rani and D. Kapoor, “Ruptured ovarian endometrioma with an extreme rise in serum CA 125 level - A case report: Ovarian endometrioma with very high CA-125 level,” Gynecologic Oncology Reports, vol. 2, no. 3, pp. 100-101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Duran, A. Kosus, N. Kosus, C. Duvan, and H. Kafali, “Treatment of ruptured ovarian endometrioma with extremely high CA 125, moderately high CA 19-9 and CA 15-3 Level,” Journal of Clinical and Analytical Medicine, vol. 4, no. 3, pp. 299-300, 2013. View at Google Scholar
  11. L. Dereli, U. Solmaz, E. Mat, N. Peker, A. Dogan, and B. Yildirim, “Huge endometrioma with severe ascites mimicking ovarian cancer,” Journal of Cases in Obstetrics & Gynecology, vol. 1, no. 3, pp. 49-50, 2014. View at Google Scholar
  12. X. Dai, C. Jin, Y. Hu et al., “High CA-125 and CA19-9 levels in spontaneous ruptured ovarian endometriomas,” Clinica Chimica Acta, vol. 450, pp. 362–365, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Yilmazer, M. Sonmezer, M. Gungor, V. Fenkci, and S. Cevrioglu, “Unusually elevated serum carbohydrate antigen 125 (CA125) and CA19-9 levels as a result of unruptured bilateral endometrioma,” Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 43, no. 4, pp. 329-330, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. C. S. Shiau, M. Y. Chang, C. H. Chiang, C. C. Hsieh, and T. T. Hsieh, “Ovarian endometrioma associated with very high serum CA-125 levels,” Chang Gung Medical Journal, vol. 26, no. 9, pp. 695–699, 2003. View at Google Scholar
  15. C. S. Atabekoglu, M. Sönmezer, B. Aydinuraz, and I. Dünder, “Extremely elevated CA 125 level due to an unruptured large endometrioma,” European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 110, no. 1, pp. 105-106, 2003. View at Google Scholar
  16. K. Kahraman, I. Ozguven, M. Gungor, and C. S. Atabekoglu, “Extremely elevated serum CA-125 level as a result of unruptured unilateral endometrioma: the highest value reported,” Fertility and Sterility, vol. 88, no. 4, pp. e15–e17, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. Hosseini, A. Aleyasin, S. Khodaverdi, A. Mahdavi, and Z. Najmi, “Extra-ordinary High CA-125 and CA19-9 Serum levels in an ovarian endometrioma: case report,” Journal of Family Planning and Reproductive Health Care, vol. 3, no. 2, pp. 67–70, 2009. View at Google Scholar
  18. N. Peker, A. Demir, and O. Bige, “Endometrioma mimicking ovarian cancer with unusual high levels of serum CA 125 and CA 19-9,” Basic and Clinical Sciences, vol. 2, pp. 170–173, 2013. View at Google Scholar
  19. R. C. Bast Jr., M. Feeney, H. Lazarus, L. M. Nadler, R. B. Colvin, and R. C. Knapp, “Reactivity of a monoclonal antibody with human ovarian carcinoma,” The Journal of Clinical Investigation, vol. 68, no. 5, pp. 1331–1337, 1981. View at Publisher · View at Google Scholar · View at Scopus
  20. E. R. Myers, L. A. Bastian, L. J. Havrilesky, S. L. Kulasingam, M. S. Terplan, K. E. Cline et al., “Management of adnexal mass,” Evidence Report/Technology Assessment, vol. 130, pp. 1–145, 2006. View at Google Scholar
  21. T. A. D. Timmerman, T. Bourne, E. Ferrazzi, L. Ameye, M. L. Konstantinovic et al., “Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the international ovarian tumor analysis group,” Journal of Clinical Oncology, vol. 23, pp. 8794–8801, 2005. View at Google Scholar
  22. G. J. Rustin, R. C. Bast, G. Kelloff, J. Barrett, S. Carter, P. Nisen et al., “Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer,” Clinical Cancer Research, vol. 10, pp. 3919–3926, 2004. View at Google Scholar
  23. RCOG, “Management of Suspected Ovarian Masses in Premenopausal Women (Green-top Guideline No. 62),” 2011.
  24. B. W. Mol, N. Bayram, J. G. Lijmer, M. A. Wiegerinck, M. Y. Bongers, F. van der Veen et al., “The performance of CA-125 measurement in the detection of endometriosis: a meta-analysis,” Fertility and Sterility, vol. 70, pp. 1101–1108, 1998. View at Google Scholar
  25. Y.-M. Cheng, S.-T. Wang, and C.-Y. Chou, “Serum CA-125 in preoperative patients at high risk for endometriosis,” Obstetrics & Gynecology, vol. 99, no. 3, pp. 375–380, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. Gynecologists TACoOa, “Practice bulletin no. 114: management of endometriosis,” Obstetrics and Gynecology, vol. 116, no. 1, pp. 223–236, 2010. View at Google Scholar
  27. M. D. Hornstein, B. L. Harlow, P. P. Thomas, and J. H. Check, “Use of a new CA125 assay in the diagnosis of endometriosis,” Human Reproduction, vol. 10, pp. 932–934, 1995. View at Google Scholar
  28. E. Donald, M. D. Pittaway, and J. A. Fazyez, “Serum CA-125 antigen levels increase during menses,” American Journal of Obstetrics & Gynecology, vol. 156, no. 1, pp. 75-76, 1987. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Jacobs and R. C. Bast Jr., “The CA 125 tumour-associated antigen: a review of the literature,” Human Reproduction, vol. 4, no. 1, pp. 1–12, 1989. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Uharček, M. Mlyncek, and J. Ravinger, “Elevation of serum CA 125 and D-Dimer levels associated with rupture of ovarian endometrioma,” The International Journal of Biological Markers, vol. 22, no. 3, pp. 203–205, 2007. View at Publisher · View at Google Scholar
  31. P. R. Koninckx, M. Muyldermans, P. Moerman, C. Meuleman, J. Deprest, and F. Cornillie, “CA 125 concentrations in ovarian 'chocolate' cyst fluid can differentiate an endometriotic cyst from a cystic corpus luteum,” Human Reproduction, vol. 7, no. 9, pp. 1314–1317, 1992. View at Google Scholar
  32. B. J. Park, T. E. Kim, and Y. W. Kim, “Massive peritoneal fluid and markedly elevated serum CA125 and CA19-9 levels associated with an ovarian endometrioma,” The Journal of Obstetrics and Gynaecology Research, vol. 35, p. 935, 2009. View at Google Scholar
  33. V. F. Amaral, R. A. Ferriani, M. F. Sa et al., “Positive correlation between serum and peritoneal fluid CA-125 levels in women with pelvic endometriosis,” São Paulo Medical Journal, vol. 124, pp. 223–227, 2006. View at Google Scholar
  34. A. Barbati, M. M. Anceschi, G. C. Di Renzo, and E. V. Cosmi, “CA 125 in peritoneal fluid: reliable values at high dilutions,” Obstetrics and gynecology, vol. 79, no. 6, pp. 1011–1015, 1992. View at Google Scholar
  35. P. R. Koninckx, L. Riittinen, M. Seppala, and F. J. Cornillie, “CA-125 and placental protein 14 concentrations in plasma and peritoneal fluid of women with deeply infiltrating pelvic endometriosis,” Fertility and Sterility, vol. 57, pp. 523–530, 1992. View at Google Scholar